Related references
Note: Only part of the references are listed.Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis
Laura Romero-Perez et al.
HUMAN PATHOLOGY (2013)
Immunohistochemical features of post-radiation vaginal recurrences of endometrioid carcinomas of the endometrium: role for proteins involved in resistance to apoptosis and hypoxia
Maria Santacana et al.
HISTOPATHOLOGY (2012)
Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells
Anabel Sorolla et al.
MOLECULAR ONCOLOGY (2012)
Prognostic Significance of miR-205 in Endometrial Cancer
Mihriban Karaayvaz et al.
PLOS ONE (2012)
Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas
Keiko Shoji et al.
PLOS ONE (2012)
KSR1 Is Overexpressed in Endometrial Carcinoma and Regulates Proliferation and TRAIL-Induced Apoptosis by Modulating FLIP Levels
David Llobet et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Mutation and Loss of Expression of ARID1A in Uterine Low-grade Endometrioid Carcinoma
Bin Guan et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2011)
PIK3R1 (p85α) Is Somatically Mutated at High Frequency in Primary Endometrial Cancer
Mary E. Urick et al.
CANCER RESEARCH (2011)
miR-152 Is a Tumor Suppressor microRNA That Is Silenced by DNA Hypermethylation in Endometrial Cancer
Tomohiko Tsuruta et al.
CANCER RESEARCH (2011)
A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial Carcinomas
Meghan L. Rudd et al.
CLINICAL CANCER RESEARCH (2011)
Promoter hypermethylation and expression of sprouty 2 in endometrial carcinoma
Ana Velasco et al.
HUMAN PATHOLOGY (2011)
Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma
Maria Angeles Castilla et al.
JOURNAL OF PATHOLOGY (2011)
Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas
Kimberly C. Wiegand et al.
JOURNAL OF PATHOLOGY (2011)
FGFR2 alterations in endometrial carcinoma
Sonia Gatius et al.
MODERN PATHOLOGY (2011)
Nuclear factor-κB2/p100 promotes endometrial carcinoma cell survival under hypoxia in a HIF-1α independent manner
Andree Yeramian et al.
LABORATORY INVESTIGATION (2011)
The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms
D. Llobet et al.
EUROPEAN JOURNAL OF CANCER (2010)
Molecular alterations in uterine serous carcinoma
Monica Prasad Hayes et al.
GYNECOLOGIC ONCOLOGY (2010)
MicroRNA signatures differentiate uterine cancer tumor subtypes
Elena S. Ratner et al.
GYNECOLOGIC ONCOLOGY (2010)
Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations
Lluis Catasus et al.
MODERN PATHOLOGY (2010)
Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms
Laura J. Tafe et al.
MODERN PATHOLOGY (2010)
A coding-independent function of gene and pseudogene mRNAs regulates tumour biology
Laura Poliseno et al.
NATURE (2010)
PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors
Konstantin J. Dedes et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
CK2 beta Is Expressed in Endometrial Carcinoma and Has a Role in Apoptosis Resistance and Cell Proliferation
Judit Pallares et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma
Monica Prasad Hayes et al.
GYNECOLOGIC ONCOLOGY (2009)
Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints
D. Llobet et al.
JOURNAL OF CLINICAL PATHOLOGY (2009)
Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis
Lluis Catasus et al.
MODERN PATHOLOGY (2009)
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
Violeta Serra et al.
CANCER RESEARCH (2008)
Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma
Judit Pallares et al.
MODERN PATHOLOGY (2008)
Drug-sensitive FGFR2 mutations in endometrial carcinoma
Amit Dutt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells
D. Llobet et al.
ONCOGENE (2008)
Long, abundantly expressed non-coding transcripts are altered in cancer
Damon S. Perez et al.
HUMAN MOLECULAR GENETICS (2008)
Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes
P. M. Pollock et al.
ONCOGENE (2007)
Essential role for nuclear PTEN in maintaining chromosomal integrity
Wen Hong Shen et al.
CELL (2007)
PIK3CA gene mutations in endometrial carcinoma.: Correlation with PTEN and K-RAS alterations
Ana Velasco et al.
HUMAN PATHOLOGY (2006)
Proteasome inhibitors induce death but activate NF-κB on endometrial carcinoma cell lines and primary culture explants
Xavier Dolcet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Low frequency of BRAF mutations in endometrial and in cervical carcinomas
Gerna Moreno-Bueno et al.
CLINICAL CANCER RESEARCH (2006)
HER-2 is an independent prognostic factor in endometrial cancer: Association with outcome in a large cohort of surgically staged patients
C Morrison et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma
K Oda et al.
CANCER RESEARCH (2005)
FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis
X Dolcet et al.
LABORATORY INVESTIGATION (2005)
Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling
JI Risinger et al.
CANCER RESEARCH (2005)
Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer
GL Maxwell et al.
CLINICAL CANCER RESEARCH (2005)
Distinctive gene expression profiles by cDNA microarrays in endometrioid and serous carcinomas of the endometrium
QJ Cao et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2004)
Abnormalities in the NF-κB family and related proteins in endometrial carcinoma
J Pallares et al.
JOURNAL OF PATHOLOGY (2004)
Abnormalities of the APC/β-catenin pathway in endometrial cancer
G Moreno-Bueno et al.
ONCOGENE (2002)
CTNNB1 mutations and β-catenin expression in endometrial carcinomas
P Machin et al.
HUMAN PATHOLOGY (2002)
Molecular pathology of endometrial hyperplasia and carcinoma
X Matias-Guiu et al.
HUMAN PATHOLOGY (2001)
Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers
GL Mutter et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
PTEN mutations in endometrial carcinomas: A molecular and clinicopathologic analysis of 38 cases
E Bussaglia et al.
HUMAN PATHOLOGY (2000)
Share Paper
